Currently, 3 recruiting clinical phase-I studies are investigating the clinical response, safety, and pharmacokinetics of using CD4-specific CARTs in patients with CD4 + T cell leukemias/lymphomas (NCT04162340, NCT04219319, NCT03829540). The gene discussed is CD4; the disease is lymphoma.